Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Insulet Corporation

Rank #48HypergrowthWatchlistCompare with other stocks

PODD · Nasdaq · Healthcare

Insulet Corporation (PODD) — Rank #48 by gross profitability (GP/assets 0.61) · ROE 17.4% · Piotroski F-Score N/A.

As-of 2026-10-30 · CIK 0001145197 · all metrics point-in-time as of the filing date.

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.

Show more

The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors.

Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Industry
Medical Devices
Sector
Healthcare
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/S is the primary valuation lens — earnings are reinvested, not available for P/E.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

5,400

Industry

Medical Devices

Exchange

Nasdaq

12/12

Flags passed

PODD passes 12/12 quality flags

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Revenue growth accelerating · Operating leverage expanding · Deferred revenue growing · Sequential beat (rev + EPS)

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.61
Return on equity
17.4%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
1.23
Current ratio
2.48×
Net cash
$516.00M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
2.3%

Growth

2/2 pass
Revenue growth
30.7%
Piotroski F-Score
N/A
Share dilution
-2.7%

Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 74th percentile of 20 SIC 3841 peers

Gross profitability (GP / assets)

0.61

Primary signal (Novy-Marx).

74th pctl of 20 SIC 3841 peers

Return on equity

17.4%

Gross margin

71.6%

89th pctl of 20 SIC 3841 peers

Revenue growth (YoY)

30.7%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

27.5%

Revenue CAGR (5Y)

24.5%

Earnings CAGR (3Y)

277.3%

FCF CAGR (3Y)

—

Cash Flow Health

Is the cash real?

No warning flags · FCF 53% above net income

Free cash flow

$377.70M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

52.9%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

2.3%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

No warning flags · net cash $516.00M

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

1.23

16th of 19 SIC 3841 peers (best = lowest)

Current ratio

2.48×

37th pctl of 20 SIC 3841 peers

Quick ratio

1.51×

Net cash

$516.00M

Cash & equivalents minus total debt.

Piotroski F-Score

N/A

Only 8/9 components determinable.

Valuation

Is the price reasonable?

No warning flags

Valuation History

Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.

P / E

Price / diluted EPS

74.1xFair
48.9xmed 569.1x4207.6x

P / S

Price / revenue per share

6.8xCheap
6.8xmed 12.9x19.1x

P / B

Price / book value per share

12.2xCheap
12.2xmed 23.6x43.2x

P / GP

Price / gross profit per share

9.6xCheap
9.6xmed 18.9x29.7x

P / FCF

Price / free cash flow per share

49.1xCheap
49.1xmed 68.4x194.1x

Capital allocation quality

Composite score

3.2 / 5

Good
Share count trend(net buybacks)
-2.7%4/5 Strong
Buyback timing
vs own P/E history5/5 Strong
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory
-5.4%1/5 Weak

Lifecycle Phase History

20202025
Hypergrowth
Op. Leverage

Price History

PODD-52.8% · -13.9% CAGRSPY+84.0% · +12.9% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports